Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : PCES - paid $4.75 Million by 3M Corp!!! -- Ignore unavailable to you. Want to Upgrade?

To: stockman_scott who wrote (335)	9/18/1999 3:32:00 PM
From: dexx	Respond to of 523

Wow! PCES closed at .31 x .35 ! I had to leave before the market closed yesterday and just now looked up the closing price. Sure looks like John Pappajohn has something good brewing. Time will tell... but I've just tightened my grip on my PCES shares for safety. Dexx

To: stockman_scott who wrote (335)	9/19/1999 7:52:00 PM
From: makin_dough99	Read Replies (1) \| Respond to of 523

I like PCES as the shell it is, but it makes no sense for PCES to merge with another company that is already public like MCIF - does not make any sense. I hope PCES finds a GREAT non-public merger candidate.

To: stockman_scott who wrote (335)	9/20/1999 2:50:00 PM
From: Brad	Read Replies (3) \| Respond to of 523

Scott, Mr Pappajohn has interests in several private companies that have plans to go public. Here is ONE example... Analytika, Inc - The North Carolina News Observer reported about 18 months ago that Analytika was raising venture capital and wanted to go public. news-observer.com Analytika, Inc has an agreement with Glaxo Wellcome, Inc (NYSE: GLX). "Under the terms of the Agreement, Analytika will perform integrated analytical activities in support of the Health Management Division, the Care Management Division, and other divisions and groups within Glaxo Wellcome Inc." ""Analytika's data mining capabilities and emphasis on the pharmaceutical industry make them a good fit for Glaxo Wellcome," said John Paul, Ph.D., Director of Clinical Economics in Glaxo Wellcome's Care Management Division." analytika.com Here is a description of what Analytika does (from their website)... "Analytika, Inc., based in Research Triangle Park, NC, integrates data management, intelligent data analysis, Internet technology, and life sciences expertise to deliver competitive advantage from aggregated data." "Analytika's client list includes major pharmaceutical firms, HMOs and other managed care organizations, drug discovery houses, contract research organizations, and healthcare insurers." Could Analytika, Inc be a potential prospect for the PCES shell?